Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BRDT | SNV | Missense_Mutation | | c.2383N>G | p.Gln795Glu | p.Q795E | Q58F21 | protein_coding | tolerated(0.21) | benign(0.007) | TCGA-A2-A0EQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
BRDT | SNV | Missense_Mutation | | c.1205N>A | p.Gly402Asp | p.G402D | Q58F21 | protein_coding | tolerated(0.15) | benign(0.03) | TCGA-A2-A0SV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate therapy | zometa | PD |
BRDT | SNV | Missense_Mutation | | c.1075N>A | p.Asp359Asn | p.D359N | Q58F21 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRDT | SNV | Missense_Mutation | rs781696685 | c.1370A>G | p.Glu457Gly | p.E457G | Q58F21 | protein_coding | tolerated(0.37) | possibly_damaging(0.757) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRDT | SNV | Missense_Mutation | | c.180N>T | p.Lys60Asn | p.K60N | Q58F21 | protein_coding | tolerated(0.06) | possibly_damaging(0.874) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
BRDT | SNV | Missense_Mutation | | c.1637C>G | p.Pro546Arg | p.P546R | Q58F21 | protein_coding | deleterious(0) | probably_damaging(0.915) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
BRDT | insertion | In_Frame_Ins | novel | c.558_559insGATGAGATAGAGATAGACTTTGAAACACTG | p.Pro186_Lys187insAspGluIleGluIleAspPheGluThrLeu | p.P186_K187insDEIEIDFETL | Q58F21 | protein_coding | | | TCGA-D8-A1JL-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BRDT | SNV | Missense_Mutation | rs148311319 | c.623C>T | p.Ala208Val | p.A208V | Q58F21 | protein_coding | tolerated(1) | benign(0) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
BRDT | SNV | Missense_Mutation | | c.599N>T | p.Ser200Leu | p.S200L | Q58F21 | protein_coding | tolerated(0.5) | benign(0.001) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
BRDT | SNV | Missense_Mutation | | c.2459C>T | p.Ser820Leu | p.S820L | Q58F21 | protein_coding | deleterious(0.05) | possibly_damaging(0.691) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | TRIAZOLAM | TRIAZOLAM | 22137933 |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | PMID26924192-Compound-103 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | inhibitor | 187051813 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | PMID26924192-Compound-104 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | (+)-JQ1 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | PMID26924192-Compound-105 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | MIDAZOLAM | MIDAZOLAM | 22137933 |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | inhibitor | 187051825 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | PMID26924192-Compound-102 | | |
676 | BRDT | DRUGGABLE GENOME, SERINE THREONINE KINASE, KINASE | | ALPRAZOLAM | ALPRAZOLAM | 22137933 |